Abstract

Recent studies have revealed the importance of long noncoding RNAs (lncRNAs) as tissue-specific regulators of gene expression. There is ample evidence that distinct types of vasculature undergo tight transcriptional control to preserve their structure, identity, and functions. We determine a comprehensive map of lineage-specific lncRNAs in human dermal lymphatic and blood vascular endothelial cells (LECs and BECs), combining RNA-Seq and CAGE-Seq. Subsequent antisense oligonucleotide-knockdown transcriptomic profiling of two LEC- and two BEC-specific lncRNAs identifies LETR1 as a critical gatekeeper of the global LEC transcriptome. Deep RNA-DNA, RNA-protein interaction studies, and phenotype rescue analyses reveal that LETR1 is a nuclear trans-acting lncRNA modulating, via key epigenetic factors, the expression of essential target genes, including KLF4 and SEMA3C, governing the growth and migratory ability of LECs. Together, our study provides several lines of evidence supporting the intriguing concept that every cell type expresses precise lncRNA signatures to control lineage-specific regulatory programs.

Long noncoding RNAs regulate tissue-specific gene expression. Here the authors profile lineage-specific lncRNAs in human dermal lymphatic and blood vascular endothelial cells (LECs and BECs) and show a role of LEC-specific lncRNA, LETR1, in cell proliferation and migration.

Details

Title
LETR1 is a lymphatic endothelial-specific lncRNA governing cell proliferation and migration through KLF4 and SEMA3C
Author
Ducoli Luca 1 ; Agrawal Saumya 2 ; Sibler Eliane 1   VIAFID ORCID Logo  ; Kouno Tsukasa 2 ; Tacconi Carlotta 3   VIAFID ORCID Logo  ; Chung-Chao, Hon 2   VIAFID ORCID Logo  ; Berger, Simone D 3 ; Müllhaupt Daniela 3 ; He, Yuliang 4 ; Kim, Jihye 3 ; D’Addio Marco 3 ; Dieterich, Lothar C 3   VIAFID ORCID Logo  ; Carninci Piero 2   VIAFID ORCID Logo  ; de Hoon Michiel J L 5 ; Shin, Jay W 5   VIAFID ORCID Logo  ; Detmar, Michael 3   VIAFID ORCID Logo 

 Swiss Federal Institute of Technology (ETH) Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Swiss Federal Institute of Technology and University of Zurich, Molecular Life Sciences PhD Program, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780) 
 RIKEN Center for Integrative Medical Sciences, Yokohama, Japan (GRID:grid.5801.c); RIKEN Center for Life Science Technologies, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255) 
 Swiss Federal Institute of Technology (ETH) Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780) 
 Swiss Federal Institute of Technology (ETH) Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Swiss Federal Institute of Technology and University of Zurich, Molecular and Translational Biomedicine PhD Program, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780) 
 RIKEN Center for Integrative Medical Sciences, Yokohama, Japan (GRID:grid.7597.c); RIKEN Center for Life Science Technologies, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2488039769
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.